Kálium-Klorid B.Braun

Potassium Chloride, the active ingredient in Kálium-Klorid B.Braun, is an electrolyte (potassium salt) presented as an intravenous solution for intravenous use. It treats hypokalemia and provides potassium replacement therapy in patients who require electrolyte correction.

GNH USA supplies Kálium-Klorid B.Braun as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Potassium Chloride is used intravenously to correct potassium deficits in disorders of electrolyte balance.

Hypokalemia: restores serum potassium levels to the normal range. Potassium replacement therapy: provides controlled potassium supplementation during intravenous fluid therapy. Post‑operative electrolyte management: corrects potassium deficits that may arise after surgery.

Potassium Chloride administered intravenously may be associated with several adverse reactions.

Common Side Effects: - Injection site pain or irritation - Transient hyperkalemia - Nausea - Metallic taste

Serious or Rare Side Effects: - Severe hyperkalemia leading to cardiac arrhythmia - Anaphylactic reaction - Extravasation causing tissue necrosis

When using Kálium-Klorid B.Braun, consider the following precautions.

Renal impairment: monitor serum potassium and adjust infusion rate. Cardiac disease: avoid rapid infusion in patients with arrhythmias. Concomitant potassium‑sparing diuretics: increase risk of hyperkalemia. Acid‑base disorders: correct underlying condition before administration. Blood glucose control: monitor in diabetic patients as potassium shifts may affect glucose. Store at ambient temperature: keep in original container, protect from light and moisture.

Potassium Chloride can interact with several medications; awareness of interaction severity is essential.

Major Interactions (Avoid): - ACE inhibitors or ARBs: may cause additive hyperkalemia. - Potassium‑sparing diuretics (e.g., spironolactone): increase risk of severe hyperkalemia. - NSAIDs: can reduce renal potassium excretion, raising serum levels.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask symptoms of hyperkalemia. - Digitalis glycosides: hyperkalemia can potentiate toxicity. - Insulin or glucose therapy: shifts potassium intracellularly, may require monitoring.